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Introduction 
Many disease states are caused by miss-regulated neurotransmission. A small fraction of these 
diseases can currently be treated with botulinum neurotoxin type A (BoNT/A). BoNT/A is 
composed of three functional domains – the light chain (Lc) is a zinc metalloprotease that 
cleaves intracellular SNAP25 which inhibits exocytosis, the translocation domain (Td) that 
enables the export of the light chain from the endosome to the cytosol, and the receptor binding 
domain (Rbd) that binds to extracellular gangliosides and synaptic vesicle glycoproteins while 
awaiting internalisation [1]. Current endeavours are directed towards retargeting Bont/A as well 
as finding safer methods of preparation and administration. Recently, our laboratory has 
developed a SNARE based linking strategy to recombine non-toxic BoNT/A fragments into a 
functional protein by simple mixing [2]. This SNARE based linking strategy permits the step-
wise assembly of highly stable macromolecular complexes [2,3]. Onto these three SNARE 
peptides, diverse functional groups can be attached to the N- or C- terminus by direct synthesis 
and/or by genetic design. To enhance the therapeutic potential of BoNT/A, this method enables 
the rapid assembly of a large array of neuropeptide-SNAREs to their cognate LcTd-SNARE. A 
substitution of the Rbd with various neuropeptide sequences permits a large throughput 
combinatorial assay of LcTd to target new cell types. In this study, we have fused LcTd to 3 
different Synaptobrevin sequences; we also use a small protein staple, and 26 different 
Syntaxin-neuropeptide fusions (permitting the assay of 78 new chimeric LcTd proteins with 
modified targeting domains). These neuropeptides such as, but not exclusively, somatostatin 
(SS), vasoactive intestinal peptide, 
substance P, opioid peptide analo-
gues, Gonadotropin releasing hor-
mone, and Arginine Vasopressin, 
which natively function through G 
protein coupled receptors (GPCR) 
can undergo agonist induced 
internalisation upon activation. 
The ability of our new constructs, 
once endocytosed, to inhibit 
neurotransmitter release was tested 
on different neuronal cell lines 
with immunoblotting of endo-
genous SNAP25. This cleavage by 
Lc reflects the ultimate readout of 
the enzyme’s efficacy, which 
incorporates the cell surface 
binding, internalisation kinetics, translocation of the Lc to the cytosol, and finally the enzymatic 
cleavage of SNAP25. Internalisation of the toxins can also be monitored with confocal 
microscopy and FACS by the substitution of the staple peptide for a fluorescent homologue. 
Figure 1 shows that whole boNT/A (upper left) can have its Rbd replaced with SNARE 
peptides, which will fuse together to form highly stable chimeric proteins with an altered 
targeting domain (right). Figure 1 also shows 4 different neuropeptide synthaxins in complex, 
resolved on SDS-PAGE gel (bottom left lanes 1-4, boiled 1’-4’). 
 
 
 
Fig. 1. SNARE-linked botulinum neurotoxins used for the
retargeting of Bont/A.
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 Results and Discussion 
The reassembled toxins were tested on mouse neuroblastoma 2A (N2A), rat pheocytochroma 
(PC-12), human neuroblastoma (SH-5YSY) cells as well as rat hippocampus, cortex and dorsal 
root ganglion neurons at nM concentrations from 18 to 42h. The resulting cleavage bands, as 
revealed by western immunoblotting, were quantified as previously described [4]. Figure 2 
shows a typical example 
of a SNAP25 cleavage 
assay. The same con-
centration of LcHn-
BrevinC can have vari-
able efficacy once pre-
complexed with various 
neuropeptide targeting 
domains. As a noted 
example, we can see 
that the LcHn/Der-
morphin complex has 
higher efficacy on N2A 
cells as well as on 
hippocampus neurons 
compared to the use of 
other Syntaxins, while 
LcHn-SS has a higher 
efficacy on Hippocampus neurons. These results could reflect the cell surface expression of 
opioid and somatostatin receptors respectively, as well as the permissive structure activity of 
each neuropeptide in complex. 
To this end, further structural refinement of the peptides implicated in these complexes 
could capitulate a higher potency and more selective medicinal enzyme. SNARE peptide 
stapling facilitates these structural refinements. Modifications in the SNARE motifs could 
enhance the versatility of the staple peptide, while modifications of the new targeting domains 
and its cross-linkers could enhance the structure activity (i.e. binding affinities, internalization 
activity). The SNARE based protein stapling is thus a versatile avenue for the efficient and high 
throughput subunit rearrangement of diverse protein that can exploit the advantages of both 
direct synthesis and recombinant expression to yield interesting de novo protein assemblies. 
Assembled LcTd-SNARE complexes have also demonstrated to be important cell 
penetrating moieties (as well as BoNT/A fragments individually; data not shown), this ability 
can be advantageous to enhance the cell penetration of chimeric proteins of diverse interest that 
have been assembled using SNARE protein stapling. Our results have also shown that the 
internalized BoNT/A-SNARE complexes (with fluorescent staple) co-localize with acidic 
organelles inside cells (data not shown); a necessary step in the intracellular activation of the 
light chain. Current endeavors are also directed towards minimizing the cell penetrating 
properties of SNARE peptides to lead to exclusive endocytosis via GPCR internalization and 
minimizing any potential off target side effects. 
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Fig. 2. SNAP25 cleavage assay on rat hippocampal neurons (left)
and N2A cells (right) with corresponding densitometric analysis.  
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